Maternal Floor Infarction/Massive Perivillous Fibrin Deposition: A Manifestation of Maternal Antifetal Rejection?
Article first published online: 1 AUG 2013
© Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
American Journal of Reproductive Immunology
Volume 70, Issue 4, pages 285–298, October 2013
How to Cite
Maternal Floor Infarction/Massive Perivillous Fibrin Deposition: a manifestation of maternal antifetal rejection? Am J Reprod Immunol 2013; 70: 285–298, , , , , , , , .
- Issue published online: 13 SEP 2013
- Article first published online: 1 AUG 2013
- Manuscript Accepted: 7 MAY 2013
- Manuscript Received: 18 APR 2013
- Perinatology Research Branch
- Division of Intramural Research
- National Institute of Child Health and Human Development
- National Institutes of Health
- Department of Health and Human Services
- NICHD, NIH. Grant Number: HSN275201300006C
- Fibrinoid deposition;
- HLA ;
- plasma cell deciduitis;
Massive perivillous fibrin deposition (MPFD) and maternal floor infarction (MFI) are related placental lesions often associated with fetal death and fetal growth restriction. A tendency to recur in subsequent pregnancies has been reported. This study was conducted to determine whether this complication of pregnancy could reflect maternal antifetal rejection.
Pregnancies with MPFD were identified (n = 10). Controls consisted of women with uncomplicated pregnancies who delivered at term without MPFD (n = 175). Second-trimester maternal plasma was analyzed for panel-reactive anti-HLA class I and class II antibodies. The prevalence of chronic chorioamnionitis, villitis of unknown etiology, and plasma cell deciduitis was compared between cases and controls. Immunohistochemistry was performed on available umbilical vein segments from cases with MPFD (n = 4) to determine whether there was evidence of complement activation (C4d deposition). Specific maternal HLA-antibody and fetal HLA-antigen status were also determined in paired specimens (n = 6). Plasma CXCL-10 concentrations were measured in longitudinal samples of cases (n = 28 specimens) and controls (n = 749 specimens) by ELISA. Linear mixed-effects models were used to test for differences in plasma CXCL-10 concentration.
(i) The prevalence of plasma cell deciduitis in the placenta was significantly higher in cases with MPFD than in those with uncomplicated term deliveries (40% versus 8.6%, P = 0.01), (ii) patients with MPFD had a significantly higher frequency of maternal anti-HLA class I positivity during the second trimester than those with uncomplicated term deliveries (80% versus 36%, P = 0.01); (iii) strongly positive C4d deposition was observed on umbilical vein endothelium in cases of MPFD, (iv) a specific maternal antibody against fetal HLA antigen class I or II was identified in all cases of MPFD; and 5) the mean maternal plasma concentration of CXCL-10 was higher in patients with evidence of MPFD than in those without evidence of MFPD (P < 0.001).
A subset of patients with MPFD has evidence of maternal antifetal rejection.